News

Ghent, Belgium, 28th May 2025 Ardena, a specialist service provider in integrated drug development, today announced a new milestone at its newly established bioanalytical laboratory at Pivot Park in Oss, Netherlands. Following successful commissioning of the facility earlier this year, the site has already initiated several client projects and completed its first sample testing earlier […]

Ghent, Belgium, 4th February 2025 Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) with facilities in Belgium, Spain, the Netherlands, and Sweden, today announced that it has successfully completed the acquisition of Catalent’s state-of-the-art drug product manufacturing facility in Somerset, New Jersey. This acquisition marks a significant […]

Oss, The Netherlands — Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands, and Sweden, announces the full Good Manufacturing Practice (GMP) approval of its expanded nanomedicine facility in Oss. Granted by the Dutch Healthcare Authority, the approval enables GMP manufacturing operations for nanomedicines, marking a […]

Ghent, Belgium, 29th October 2024 Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands and Sweden, today announced a substantial expansion of its Bioanalytical Services in the Netherlands. This strategic investment includes establishing a brand new bioanalytical lab at Ardena’s Pivot Park facility in Oss, along […]

Ghent, Belgium, 14th October 2024 Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands and Sweden, today announced it has signed a definitive agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey. This acquisition will significantly enhance Ardena’s capabilities in downstream late-stage and small-scale commercial […]

July 16, 2024 Ghent, Belgium – Ardena (the “Company”) announces several key promotions to its executive leadership team, reflecting the Company’s commitment to driving growth and international expansion and fostering diversity and talent development. Ariane De Ganck promoted to Division Head, Drug Product Services Ariane De Ganck, based in Ghent, Belgium, has been promoted to […]

June 3rd, 2024 Ghent, Belgium – Ardena (the “Company”) today announces the retirement of Harry Christiaens, PhD and the subsequent appointment of Jeremie Trochu as Chief Executive Officer. Jeremie is a seasoned executive in the pharmaceutical Contract Development and Manufacturing Operations (CDMO) industry. Harry will step down as CEO after 20 years of leading the […]

Oss, The Netherlands — Ardena, a leading Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories in its expanded nanomedicines facility. The facility includes state-of-the-art GMP-compliant cleanrooms to support Ardena’s growing nanomedicines business, as well […]

Ardena, a leading Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has been granted a Good Manufacturing Practice (GMP) license by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its state-of-the-art aseptic fill-finish facility in Ghent, Belgium. A significant step forward in Ardena’s ability to provide full-service solutions […]

This is a joint press release of Ardena and ELDICO Scientific AG October 18th 2023 – Oss, Netherlands and Villigen, Switzerland Ardena and ELDICO Scientific are proud to announce that today they have entered into a collaboration agreement. This partnership grants Ardena effortless access to ELDICO’s cutting-edge electron diffractometer, the ELDICO ED-1. Electron diffraction is […]

We are pleased to share Race Oncology’s latest announcement highlighting the agreement with Ardena for the manufacturing of their flagship RC220 bisantrene formulation. We are thrilled to join forces with Race Oncology and contribute to their groundbreaking work in advancing cancer therapies. According to Race Oncology’s CEO and Managing Director, Damian Clarke-Bruce, “We are pleased […]

Leading contract development manufacturer of nanomedicines, Ardena, has joined forces with mRNA and LNP technology specialists RiboPro to form a new strategic commercial alliance aimed at delivering improvements to the global availability of RNA-based health treatments and address a crucial skills gap in the industry. The new alliance combines Ardena’s expertise in custom development and […]